Molecular Determinants of Tissue-resident Memory T cell Fate in Acute and Chronic Infection
Project Number5P01AI132122-05
Contact PI/Project LeaderGOLDRATH, ANANDA W
Awardee OrganizationUNIVERSITY OF CALIFORNIA, SAN DIEGO
Description
Abstract Text
OVERALL SUMMARY:
Mortality from infectious diseases remains the second leading cause of death worldwide; a further toll on
human health is exacted by disease-associated morbidity. The development of new vaccines is, therefore, an
important priority for improving global health. Immunological memory is a cardinal feature of adaptive immunity
and its induction is the underlying goal of vaccination. Long-lived memory T cells mediate protection from
reinfection with previously encountered pathogens; keep chronic, opportunistic and latent pathogens at bay;
and can serve as endogenous defenders against tumor growth and metastases. The memory T cell population
is heterogeneous, typically categorized into central memory cells found in the blood and lymphoid tissues, or
effector memory cells predominantly located in the blood and non-lymphoid tissues. The recent recognition of a
third subset of memory lymphocytes, termed tissue-resident memory cells (Trm), that reside strictly within
tissues and do not recirculate requires a revision of our understanding of memory T cell differentiation. Tissue-
resident T cells provide essential sentinel protection at body surfaces such as the intestinal epithelium, and,
are now clearly understood to be among the key `first responders' in many infection settings. Although we now
know that resident-memory cells are an essential component of immune memory, little is known about the
transcriptional pathways regulating their formation, survival and function.
Improving our understanding of these topics will allow us to harness the immediate protective capacity of this
vital memory T cell population and modulate activity in the context of immunopathology. To this end, we
propose three synergistic projects that all leverage novel single-cell, genomic and computational analyses
provided by two Cores to: 1) Define the unanticipated roles of key transcription factors in Trm formation and
identify novel molecular determinants of Trm differentiation and homeostasis; 2) Identify early molecular
regulators of Trm cell fate specification within different tissues in the context of acute and chronic infections
using single-cell analyses of gene expression and computational approaches; 3) Define exhausted Trm during
chronic viral infection and identify core regulators that determine their accumulation and hypo-functional state.
Understanding the generation and homeostasis of tissue-resident memory cells will allow the exploitation of the
immediate protective capacity of this vital memory population and provide strategies to modulate this activity in
the context of immunopathology. We have assembled a team of five laboratories, which together possess the
tools and expertise to resolve the transcriptional network driving memory T cell formation and exploit this
knowledge to realize advances in regulating immunity in tissues. !
Public Health Relevance Statement
OVERALL NARRATIVE:
The recent appreciation of memory CD8+ T cell populations that strictly reside in tissues, where infections and
cellular transformation occur, provides an exciting opportunity to create new approaches to understand how
long-lived protective immunity is established and sustained in tissues to protect against infections and
malignancies. This Program Project Proposal joins the forces of five laboratories with diverse expertise to
decipher the cellular and molecular pathways leading to the generation, maintenance, and functions of these
`resident' memory T cell populations in both acute and chronic infections. By identifying the unique
transcriptional pathways and regulators of tissue-resident-memory T cells, we will discover novel targets with
the potential to inform strategic design of therapeutic and protective vaccines, the development of which are of
crucial importance to human health.!
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
804355790
UEI
UYTTZT6G9DT1
Project Start Date
17-July-2018
Project End Date
30-June-2024
Budget Start Date
01-July-2022
Budget End Date
30-June-2024
Project Funding Information for 2022
Total Funding
$1,926,207
Direct Costs
$1,254,408
Indirect Costs
$671,799
Year
Funding IC
FY Total Cost by IC
2022
National Institute of Allergy and Infectious Diseases
$1,926,207
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5P01AI132122-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P01AI132122-05
Patents
No Patents information available for 5P01AI132122-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P01AI132122-05
Clinical Studies
No Clinical Studies information available for 5P01AI132122-05
News and More
Related News Releases
No news release information available for 5P01AI132122-05
History
No Historical information available for 5P01AI132122-05
Similar Projects
No Similar Projects information available for 5P01AI132122-05